Immunological Characteristics between $\alpha\beta$ T_{DC} and $\gamma\delta$ T_{DC} Cells in the Spleen of Breast Cancer-Induced Mice

Características imunológicas entre células T_{DC} $\alpha\beta$ e T_{DC} $\gamma\delta$ no baço de camundongos com câncer de mama induzido

Polyana Barbosa Silva¹, Márcia Antoniazzi Michelin^{1,2}, Millena Prata Jammal^{1,3}
Eddie Fernando Cândido Murta^{1,3}

¹Research Institute of Oncology, Universidade Federal do Triângulo Mineiro, Uberaba, MG, Brazil

²Discipline of Immunology, Universidade Federal do Triângulo Mineiro, Uberaba, MG, Brazil

³Department of Gynecology and Obstetrics, Universidade Federal do Triângulo Mineiro, Uberaba, MG, Brazil

Address for correspondence Eddie Fernando Cândido Murta, Research Institute of Oncology, Federal University of The Triângulo Mineiro, Avenida Getulio Guarita, Unnumbered, 38025-440, Uberaba, MG, Brazil (e-mail: eddiemurta@mednet.com.br).

Rev Bras Ginecol Obstet 2021;43(5):368–373.

Abstract

Objective To evaluate the antitumoral role of $\gamma\delta$ T_{DC} cells and $\alpha\beta$ T_{DC} cells in an experimental model of breast cancer.

Methods Thirty female Balb/c mice were divided into 2 groups: control group ($n = 15$) and induced-4T1 group ($n = 15$), in which the mice received 2×10^5 4T1 mammary tumor cell line. Following the 28-day experimental period, immune cells were collected from the spleen and analyzed by flow cytometry for comparison of $\alpha\beta$ T_{DC} (TCR $\alpha\beta^+$ CD11c⁺MHCII⁺) and $\gamma\delta$ T_{DC} (TCR $\gamma\delta^+$ CD11c⁺MHCII⁺) cells regarding surface markers (CD4⁺ and C8⁺) and cytokines (IFN- γ , TNF- α , IL-12 and IL-17).

Results A total of 26.53% of $\gamma\delta$ T_{DC}- control group ($p < 0.0001$) - the proportion of $\alpha\beta$ T_{DC} was lower in splenic cells than $\gamma\delta$ T_{DC}; however, these 2 cell types were reduced in tumor conditions ($p < 0.0001$), and the proportion of IFN- γ , TNF- α , IL-12 and IL-17 cytokines produced by $\gamma\delta$ T_{DC} was higher than those produced by $\alpha\beta$ T_{DC}, but it decreased under conditions of tumor-related immune system response ($p < 0.0001$).

Conclusion Healthy mice engrafted with malignant cells 4T1 breast tumor presented T_{DC} with $\gamma\delta$ TCR repertoire. These cells express cytotoxic molecules of lymphocytes T, producing anti-tumor proinflammatory cytokines.

Keywords

- immunology
- breast neoplasms
- immunotherapy
- T-lymphocytes
- receptors

received
May 13, 2020
accepted
February 12, 2021

DOI <https://doi.org/10.1055/s-0041-1730286>.
ISSN 0100-7203.

© 2021. Federação Brasileira de Ginecologia e Obstetrícia. All rights reserved.

This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (<https://creativecommons.org/licenses/by/4.0/>)

Thieme Revinter Publicações Ltda., Rua do Matoso 170, Rio de Janeiro, RJ, CEP 20270-135, Brazil

Resumo

Objetivo Esclarecer o possível papel antitumoral das células T_{DC} $\gamma\delta$ e T_{DC} $\alpha\beta$ em um modelo experimental de câncer de mama.

Métodos Trinta baços de camundongos Balb/c analisados por citometria de fluxo, separados entre grupo controle ($n = 15$) e o grupo tumoral induzido por 4T1 ($n = 15$).

Resultados Presença de 26,53% de T_{DC} $\gamma\delta$ nos camundongos do grupo controle ($p < 0,0001$), proporção de T_{DC} $\alpha\beta$ menor em células esplênicas do que T_{DC} $\gamma\delta$; no entanto, estes dois tipos de células são reduzidos em condições tumorais ($p < 0,0001$), e a proporção de citocinas IFN- γ , TNF- α , IL-12 e IL-17 produzidas pelas células T_{DC} $\gamma\delta$ foi maior do que as produzidas pelas células T_{DC} $\alpha\beta$, mas foram diminuídas sob condições de resposta ao sistema imunológico relacionada ao tumor ($p < 0,0001$).

Conclusão Camundongos saudáveis induzidos ao tumor de mama 4T1 apresentaram T_{DC} com repertório TCR $\gamma\delta$. Estas células expressam moléculas citotóxicas de linfócitos T, produzindo citocinas próinflamatórias anti-tumor.

Palavras-chave

- imunologia
- neoplasias
mamárias
- imunoterapia
- linfócitos T
- receptores

Introduction

A new type of immune cell has been described, and these new cells have characteristics of innate and acquired immunity. T_{DC} cells were identified in mice and in humans as cells that express T cell receptors (TCR $\alpha\beta$) specific of T lymphocytes, and simultaneously express the CD11c markers and major histocompatibility complex class II (MHCII or HLA [Human Leukocyte Antigen] in humans), found in innate cells, mainly in dendritic cells. These molecules in the same cell confer unique characteristics and properties; they carry out functions of dendritic cells (DCs) that do not need to be activated by antigen-presenting cells (APCs). When stimulated by specific receptors, such as the family of Toll-like receptors, they can produce interleukin-2 (IL-12) cytokine, as well as process and present antigens.¹

T lymphocytes respond in a specific manner to pathogens and cancer cells by the recognition of specific antigens due to TCR (T-cell receptor) in their membrane, similar to the role of the immunoglobulins in B cells. The TCR consists of 2 polypeptide chains; ~ between 90 and 99% of all T cells have the $\alpha\beta$ TCR, but a minority has $\gamma\delta$ chains.^{2,3} Both cells originate from common thymic precursors, but the biological roles and molecular understanding of these two subsets differ substantially. The T lymphocytes that express $\alpha\beta$ TCR depend on the presentation of antigens in a defined HLA molecule to be activated, and usually are tolerant to self-peptides. On the other hand, the $\gamma\delta$ T lymphocytes do not rely on the recognition of classic HLA molecules, and the identification of tumor antigen is made by ubiquitous changes observed across many individuals, which allows these cells to not undergo the rejection process, and, consequently, they can be transferred more easily between individuals. Unlike $\alpha\beta$ T cells that have their biological role well-characterized in cancer immune surveillance, the protective role of $\gamma\delta$ cells during tumor development has only been increasingly reported over the past two decades.

The presence of tumor-infiltrating $\gamma\delta$ T lymphocytes has been associated with good prognosis in patients with mela-

noma⁴ and gastric cancer,⁵ and high levels of these types of circulating lymphocytes have been associated with reduced cancer risk, increased 5-year-disease-free and increased survival after bone marrow transplant for acute leukemia.⁶

The antitumoral ability of $\gamma\delta$ T lymphocytes is associated with their synthesis of interferon γ (IFN- γ), and of tumor necrosis factor- α (TNF- α), as well as their cytotoxic potential. Other studies have also reported the role of interleukin-17 (IL-17) produced by $\gamma\delta$ T cells, mainly when they act together with immunogenic cell death-inducing chemotherapeutic drugs.⁷

To clarify whether T_{DC} cells could also have the $\gamma\delta$ chains and the possible antitumor role of this new cell population, we investigated the T_{DC} population comparing both $\alpha\beta$ TCR and $\gamma\delta$ TCR T_{DC}, as well as their cytokines in an experimental model of mice engrafted with malignant cells.

Methods

Animals

Thirty 8-week-old female Balb/c mice, kept in the sectoral vivarium of the Oncology Research Institute (IPON, in the Portuguese acronym) of the Universidade Federal do Triângulo Mineiro (UFTM, in the Portuguese acronym), were used. During the 28-day experimental period, the animals were divided into a control group (healthy mice) and a tumor group (4T1 breast tumor cell-engrafted mice). Each group consisted of 15 animals, was housed in plastic cages under a 12-hour light/dark cycle at $21 \pm 3^\circ\text{C}$, with food and water available ad libitum. After the experimental period, the animals were euthanized by overdosing with 50 mg/kg of ketamine and 15 mg/kg of xylazine, and their spleens were removed for analysis. The present study was approved by the Ethics Committee on Animal Use of the UFTM, under number 379/2016 - CEUA/UFTM.

Tumor

The animals were selected at random, and the tumor-induced group was engrafted with 4T1 inoculated with 2×10^5 cells in

the last pair of breasts, on the left mammary gland. Tumor cells of the strain mentioned above are cells isolated from the Balb/c mice spontaneous tumor, with high proliferative, invasive, and tumorigenic power. The cells were maintained in culture in Roswell Park Memorial Institute (RPMI) medium and incubated at 37°C and 5% CO₂ (Water Jacket Incubator 3110, Thermo Fisher Scientific, Marietta, OH, USA). After the culture period, the cells were washed with 0.9% saline solution and centrifuged at 290xg at 4°C for 10 minutes and then inoculated in the group of tumor-induced by 4T1 mice.

Characterization of Immune Cells by Flow Cytometry

The spleens of the control group and of the tumor group were disclosed, filtered, and washed with saline solution, and after counting in a Neubauer chamber, 1×10^6 cells were placed in tubes suitable for the flow cytometry technique. The cells were then labeled with extracellular anti- $\gamma\delta$ TCR- antibodies (T lymphocyte receptor), anti-CD11c (adhesion molecules), anti-IA (antigen-presenting molecule), anti-CD4 (helper T lymphocytes), and anti-CD8 (cytotoxic T lymphocytes) – all antibodies acquired from BD Biosciences. After the 30-minute incubation, the cells were washed and prepared to receive the intracellular antibody labels for anti-IFN- γ , anti-TNF- α , IL-12, and IL-17 proinflammatory cytokines. To block nonspecific binding, the antimouse IgG2b Immunoglobulin G2b) - (mouse) Rabbit Monoclonal Antibody (IgG2b), anti-rat IgG2a Immunoglobulin G2a - (mouse) Rabbit Monoclonal Antibody (IgG2a), and antirat IgG2b isotypes were used. The cells were read on the BD FACSCalibur (BD Biosciences, Franklin Lakes, NJ, USA) cytometer, and the data analyzed using Flowing software.

The gating strategy used was the delimitation by size and granularity (FSCxSSC) of the spleen cells of the control and tumor groups. Subsequently, the double-positive labeling of CD11c and IA (MHCII [Major Histocompatibility Complex - class II]) was limited and, thus, the $\gamma\delta$ TCR labeling traced the $\gamma\delta$ T_{DC} cells. Within this population of $\gamma\delta$ T_{DC}, we analyzed the phenotypic and cytokine markers of interest.

Statistical Analysis

Statistical analyzes and graphs were prepared using GraphPad Prism 5.0 (GraphPad Software, San Diego, CA, USA). The Kolmogorov-Smirnov tests were used to verify the normality of the variables. Non-normal samples were analyzed by the Mann-Whitney test, both for comparison between the control group and the tumor-induced group from both profiles and for the comparison of $\alpha\beta$ T_{DC} and $\gamma\delta$ T_{DC} cell expression. The data obtained were represented with their corresponding median, minimum and maximum values. The difference found between the groups was considered statistically significant when $p < 0.05$.

Results

The flow cytometry profile shows the comparison of $\alpha\beta$ T_{DC} (TCR $\alpha\beta$ ⁺CD11c⁺ MHCII⁺) and $\gamma\delta$ T_{DC} (TCR $\gamma\delta$ ⁺CD11c⁺ MHCII⁺) cell infiltrates in the spleen of healthy mice engrafted by breast cancer 4T1 cells (►Figs. 1 a, b, c and d). When analyzing the frequency of the $\gamma\delta$ T_{DC} cell

profile (►Fig. 1a), a significant decrease was found in the tumor group, with a median of 18.11 (17.21–19.01) compared with the control group (26.53; 23.62–29.99) ($p < 0.0001$). The frequencies of both $\alpha\beta$ T_{DC} and $\gamma\delta$ T_{DC} cells were compared, and a significance was found in the tumor-induced group of both cell profiles, that is, there was a higher amount of $\alpha\beta$ T_{DC} cells (47.74; 22.97–57.36) than of $\gamma\delta$ T_{DC} cells (18.11; 17.21–19.01) in the spleen of the 4T1 tumor-induced mice group ($p < 0.0001$).

The mean fluorescence of auxiliary T lymphocyte (CD4) and cytotoxic T lymphocyte (CD8) markers present in the $\alpha\beta$ T_{DC} and $\gamma\delta$ T_{DC} cells of both groups (►Fig. 1b) was analyzed, and it was observed that the CD8 $\alpha\beta$ T_{DC} cells showed a decrease in the tumor group (764.7; 485.8–1467) in comparison with the control group (1,650; 1,292–3,418) ($p = 0.0012$). Regarding CD4 $\gamma\delta$ T_{DC} cells, a significant decrease was found in the tumor group (1,873; 1,421–2,325) compared with the control group (2,350; 2,140–2,561) ($p = 0.0009$), as well as for CD8 $\gamma\delta$ T_{DC} cells, of which there was significant decrease in the 4T1 tumor group (329.0; 292.3–692.4) compared with the control group (1,630; 1,370–1,889) ($p < 0.0001$). When comparing both cell profiles, a decrease of CD8 $\gamma\delta$ T_{DC} cells (329.0; 292.3–692.4) was found in comparison with CD8 $\alpha\beta$ T_{DC} cells (764.7; 485.8–1467) ($p < 0.001$) in the tumor group.

The mean fluorescence intensity of the cytokines produced by $\alpha\beta$ T_{DC} and $\gamma\delta$ T_{DC} cells were analyzed (►Fig. 1c). It was noticed that, for IFN- γ $\alpha\beta$ T_{DC} cells, there was a decrease in the tumor group (1,554; 705.3–1,885) compared with the control group (4,720; 4,488–6,120) ($p < 0.0001$), as well as a TNF- α $\alpha\beta$ T_{DC} decrease in the tumor group (1,655; 403.8–2,673) compared with the control group (2,877; 2,716–4,658) ($p < 0.0001$). Regarding IL-12 $\alpha\beta$ T_{DC} cells, a decrease was observed in the tumor group (1,841; 360.7–2,728) compared with the control group (3,686; 2,028–5,163) ($p = 0.0002$), as well as for IL-17 $\alpha\beta$ T_{DC} cells, which also decreased in the tumor group (578.5; 326.3–873.8) compared with the control group (4,666; 1,117–6,436) ($p < 0.0001$).

In relation to the cytokines produced by $\gamma\delta$ T_{DC} cells, a decrease in IFN- γ $\gamma\delta$ T_{DC} cells was found in the tumor group (2,349; 1,261–3,429) compared with the control group (5,972; 5,649–6,297) ($p < 0.0001$). Regarding IL-17 $\gamma\delta$ T_{DC} cells, a decrease in the tumor group (468.3; 307.1–692.2) was observed when compared with the control group (2,026; 1,563–2,489) ($p < 0.0001$).

Finally, the profiles of $\alpha\beta$ T_{DC} and $\gamma\delta$ T_{DC} cells were compared, and an increase in the IFN- γ $\gamma\delta$ T_{DC} cells of the control group (5,972; 5,649–6,297) was found, when compared with IFN- γ $\alpha\beta$ T_{DC} cells (4,720; 4,488–6,120) ($p = 0.0005$). An increase was also found in the TNF- α $\gamma\delta$ T_{DC} cells of the control group (5,972; 5,649–6,297) compared with TNF- α $\alpha\beta$ T_{DC} cells (2,877; 2,716–4,658) ($p < 0.0001$), as well as an increase in TNF- α $\gamma\delta$ T_{DC} cells in the tumor group (2,349; 1,261–3,429) in relation to TNF- α $\alpha\beta$ T_{DC} cells (1,655; 403.8–2,673) ($p = 0.0157$). There was a decrease in IL-12 $\gamma\delta$ T_{DC} cells in the control group (1,526; 1,290–1,793) compared with IL-12 $\gamma\delta$ T_{DC} cells (3,686; 2,028–5,163) ($p < 0.0001$). When comparing IL-17 $\gamma\delta$ T_{DC} cells, a decrease was found in

Fig. 1 Comparison of immunological characteristics between $\alpha\beta$ T_{DC} and $\gamma\delta$ T_{DC} cells in the control and in the tumor group. (a) Representative graph of flow cytometric analysis to identify frequency of $\alpha\beta$ T_{DC} and $\gamma\delta$ T_{DC} cells in the spleen of the control and of the tumor group. (b) Frequency analysis of $\alpha\beta$ T_{DC} and $\gamma\delta$ T_{DC} cells in the spleen of the control and of the tumor group. (c) Mean fluorescence intensity of $\alpha\beta$ T_{DC} CD4⁺/ $\gamma\delta$ T_{DC} CD8⁺ and $\gamma\delta$ T_{DC} CD4⁺/ $\gamma\delta$ T_{DC} CD8⁺ cells in the spleen of the control mice and of the tumor group. (d) Mean fluorescence intensity of $\alpha\beta$ T_{DC} IFN- γ , $\alpha\beta$ T_{DC} TNF- α , $\alpha\beta$ T_{DC} IL-12, and $\alpha\beta$ T_{DC} IL-17 and $\gamma\delta$ T_{DC} IFN- γ , $\gamma\delta$ T_{DC} TNF- α , $\gamma\delta$ T_{DC} IL-12 and $\gamma\delta$ T_{DC} IL-17 cells in the spleen of the control and of the tumor group. Representative graphs of two independent experiments, $n = 15$ each (median with range). The results were analyzed by the Mann-Whitney test to compare the mean fluorescence intensity of subtypes $\alpha\beta$ T_{DC} and $\gamma\delta$ T_{DC} cells (statistical differences represented by the dashed line). Differences were considered statistically significant at $p < 0.05$ (5%). * $p < 0.05$; ** $p < 0.001$; *** $p < 0.0001$.

the tumor group (468.3; 307.1–692.2) in relation to IL-17 $\alpha\beta$ T_{DC} cells (578.5; 326.3–873.8) ($p = 0.0157$).

Discussion

Kuka et al¹ described T_{DC} cells (TCR $\alpha\beta$ ⁺CD11c⁺MHCII⁺) as a cell subtype with properties common to polyclonal T $\alpha\beta$ cells and dendritic cells. These rare cells have a morphological similarity to dendritic cells that express intermediate levels of CD11c and present Major Histocompatibility Complex (MHC) class II antigenic molecules. Besides, these cells are also characterized by the expression of costimulatory molecules (CD80, CD86) and lymphocyte surface markers (CD3, CD4, and TCR α/β).¹

The frequency of $\alpha\beta$ T_{DC} cells described by Kuka et al¹ is of ~ 0.04% in the spleen of healthy mice. In our study, it was identified an average of 34.64% in healthy mice and of 47.74% in the group of 4T1 breast tumor cell-engrafted mice. Kuka et al¹ identified and characterized T_{DC} cells by flow cytometry by analyzing the total cells. Our study delimits an area (gate) referring to lymphocytes, size and granulation of this cell type. T_{DC} cells have similar morphology and size to T lymphocytes.¹

The presence of the cell profile for $\gamma\delta$ T_{DC} (TCR $\gamma\delta$ ⁺CD11c⁺MHCII⁺) was verified in the same conditions, and the presence of a percentage of 26.53% of $\gamma\delta$ T_{DC} in the control group and of 18.11% in mice with breast cancer ($p < 0.0001$) was found.

The present study reports that between 1 and 4% of all T cells present in the thymus, in secondary lymphoid organs, and in the lungs of adult mice are $\gamma\delta$ T lymphocytes. In mucous membranes, such as the intestinal membrane, there are 25 to 40% of this cell type, where the most significant amount is concentrated,⁸ in addition to presenting subtypes as well as phenotypic and functional dieting properties.⁹

In our studies, the effect of a systemic immune response under the influence of tumor cells, which decreased both $\alpha\beta$ T_{DC} and $\gamma\delta$ T_{DC} cells, was observed. However, when comparing these two cell profiles – $\alpha\beta$ T_{DC} and $\gamma\delta$ T_{DC} – there was a higher amount of $\alpha\beta$ T_{DC} in the 4T1 tumor-induced tumor group than $\gamma\delta$ T_{DC} ($p < 0.0001$).

The $\alpha\beta$ T cell repertoire is higher in T lymphocytes and, most of the time, they have protective antitumor activity, mainly related to human melanoma tumors.¹⁰

A study with human blood samples from 38 patients diagnosed with breast cancer compared with healthy controls showed that the proportion of $\gamma\delta$ T cells in the circulating blood of healthy controls is 1.6 times greater than in breast cancer patients.¹¹ These data corroborate with our study, since $\gamma\delta$ T_{DC} cells are present in more significant quantities in the control group ($p < 0.0001$).

Concerning $\gamma\delta$ T cells, in an antitumor immune response, pioneering studies on the immunoprotective role of these cells in mice were performed in murine models with skin cancer, which were chemically induced by carcinogens or by subcutaneous transfer of melanoma tumor lineage. From these studies, relevant roles of $\gamma\delta$ T in antitumor immunity have been described, with mechanisms mediated by the NKG2D C-type lectin-like receptor expressed on NK (NKG2D) receptor by dendritic epidermal T cells (DETCs) V γ 5+ residing in tissues.^{12,13}

Studies comparing tumor progression in mice with deficient $\gamma\delta$ T cells (due to genetic inactivation of the $\gamma\delta$ TCR receptor) versus mice with sufficient $\gamma\delta$ T cells (wild) have firmly established the protective role of $\gamma\delta$ T cells¹⁰ because it was found that $\gamma\delta$ T cells prevented the progression of chemically induced papilloma to cutaneous squamous cell carcinomas. In contrast, $\alpha\beta$ cells seemed to favor tumor progression¹⁴; the same happened with spontaneous B cell lymphomas,¹⁵ prostate cancer¹⁶ and in the transplantable model of melanoma B16-F0.¹⁷ Besides, some studies show, in the context of infections by cytomegalovirus and malaria, that $\gamma\delta$ T cells can be activated later, in the form of direct cytotoxicity, by the action of granzyme B and through stimulating effects such as the secretion of cytokines IFN- γ and TNF- α , or by the direct presentation of antigen.¹⁸

Most $\gamma\delta$ T cells, unlike $\alpha\beta$ T lymphocytes, do not exhibit CD4 or CD8 coreceptors, so antigen recognition is not restricted to antigen-presenting molecules.⁸ Thus, the expression of $\alpha\beta$ T_{DC} and $\gamma\delta$ T_{DC} cells related to helper T lymphocyte (TCD4) and cytotoxic (TCD8) markers was compared, revealing that the proportion of CD8 $\gamma\delta$ T_{DC} is less expressed in splenic cells than CD8 $\alpha\beta$ T_{DC}, but these two cell types are decreased in tumor conditions ($p < 0.0001$).

A recently conducted study comparing subsets of $\gamma\delta$ T lymphocytes in 40 patients with Chron disease demonstrated a significant decrease in this cell population, concluding that this condition can affect the immune responses against this disease.¹⁹ We believe that, like cancer, the suppressive conditions provided by them can have the same result with $\alpha\beta$ and $\gamma\delta$ T_{DC}, leading to a deficiency of this mechanism.

The central cytokines produced by $\gamma\delta$ T_{DC} presented a higher proportion of this cell type than those produced by $\alpha\beta$ T_{DC}. That is, there is a higher production of the IFN- γ , TNF- α , IL-12 cytokines in the control group, and a lower proportion of IL-17 $\gamma\delta$ T_{DC} in the group of mice with breast cancer. However, this condition decreases when there is a systemic immune response related to tumors ($p < 0.0001$).

It is inferred that $\gamma\delta$ T_{DC} cells are similar to the mechanisms exerted by $\gamma\delta$ T cells. Studies show that this cell type is an important precursor source of IFN- γ and TNF- α , which inhibits tumor growth and angiogenesis. Also, the study performed

with the combination of concanavalin A (ConA) and interleukin-2 (IL-2) demonstrated the potential for polarization and plasticity of $\gamma\delta$ T_{DC} cells, which induced the intense proliferation of these cells and the consequent production of interleukin-12 (IL-12) and interleukin-2 (IL-18).²⁰

In inflammatory conditions, a situation observed in some cancers and infections, they favor the polarization of $\gamma\delta$ T cells toward an IL-17 producing phenotype.²¹ A recent study of transcriptome sequencing in ~ 18,000 tumor masses in humans revealed that, among tumor-infiltrating leukocytes, $\gamma\delta$ T cells were strongly associated with a good prognosis.²² In our study, it was observed that $\gamma\delta$ T_{DC} in a systemic immune response is suppressed regarding $\alpha\beta$ T_{DC} cells in tumor conditions ($p = 0.0157$).

A specific type of $\gamma\delta$ T cells ($\gamma\delta$ TCD27⁺) from mice secrete the IFN- γ cytokine, responsible for inhibiting tumor angiogenesis and improving the expression of MHC class I by tumor cells, thus promoting efficiency in the responses of CD8⁺ T cells.²³ In our studies, it was observed that $\gamma\delta$ T_{DC} cells expressed IFN- γ in more significant quantities in healthy mice ($p < 0.0001$). In the study with a model of adoptive transfer of $\gamma\delta$ T cells in mice against melanoma B16-F0, it was observed that a specific subtype of $\gamma\delta$ T V γ 4⁺ (but not V γ ⁺ T cells) had the protective function dependent on its high eomesodermin expression and IFN- γ production.²⁴

Even though IFN- γ is the main cytokine produced by mouse $\gamma\delta$ T cells, IL-17 is involved in the protective responses of $\gamma\delta$ T cells in some cancer models.²⁵ Interleukin-17-producing $\gamma\delta$ T cells cooperated in mediating bladder cancer regression.²⁶ In another study, IL-17-producing $\gamma\delta$ T cells are associated with chemotherapeutic agents (such as doxorubicin) in various models of epithelial tumor transplantation and demonstrated a better antitumor response.²⁷ In our study, it was identified that IL-17-producing $\gamma\delta$ T_{DC} is less frequent in the breast cancer-induced group compared with IL17-producing T_{DC} $\alpha\beta$ ($p < 0.0001$). Thus, it can be inferred that, in a systemic antitumor response, these cells may be suppressed by tumor escape mechanisms to antitumor immune responses.

Therefore, according to the data found in the present study, we can conclude that $\gamma\delta$ T_{DC} has immunological characteristics shared with conventional effector $\alpha\beta$ T_{DC} cells. The healthy mice engrafted with 4T1 breast tumor presented T_{DC} with $\gamma\delta$ TCR repertoire. These cells express T helper and cytotoxic T lymphocyte molecules, producing antitumor proinflammatory cytokines, suggesting that $\gamma\delta$ T_{DC} could have an antitumor role, and even be used in the future in antitumor immunotherapy. However, new studies investigating its function in other tumor types are necessary.

Contributors

All authors were involved in the design and interpretation of the analyses, contributed with the writing of the manuscript, read, and approved the final manuscript.

Funding

The present research was supported by the National Council for Scientific and Technological Development

(CNPq, in the Portuguese acronym) (grant no. 30211/2015-3), the Foundation for Education and Research of Uberaba (FUNEP, in the Portuguese acronym) (grant no. 255/2012), the Higher Education Personnel Improvement Coordination (CAPES, in the Portuguese acronym), and the Research Support Foundation of the State of Minas Gerais (FAPEMIG, in the Portuguese acronym) (grant no. Rede 11/14).

Conflict to Interests

The authors have no conflict of interests to declare.

References

- Kuka M, Munitic I, Ashwell JD. Identification and characterization of polyclonal $\alpha\beta$ -T cells with dendritic cell properties. *Nat Commun*. 2012;3:1223. Doi: 10.1038/ncomms2223
- Gaulard P, Bourquelot P, Kanavaros P, Haioun C, Le Couedic JP, Divine M, et al. Expression of the alpha/beta and gamma/delta T-cell receptors in 57 cases of peripheral T-cell lymphomas. Identification of a subset of gamma/delta T-cell lymphomas. *Am J Pathol*. 1990;137(03):617–628
- Legut M, Cole DK, Sewell AK. The promise of $\gamma\delta$ T cells and the $\gamma\delta$ T cell receptor for cancer immunotherapy. *Cell Mol Immunol*. 2015;12(06):656–668. Doi: 10.1038/cmi.2015.28
- Donia M, Ellebaek E, Andersen MH, Straten PT, Svane IM. Analysis of V δ 1 T cells in clinical grade melanoma-infiltrating lymphocytes. *Oncol Immunology*. 2012;1(08):1297–1304. Doi: 10.4161/onci.21659
- Wang J, Lin C, Li H, Li R, Wu Y, Liu H, et al. Tumor-infiltrating $\gamma\delta$ T cells predict prognosis and adjuvant chemotherapeutic benefit in patients with gastric cancer. *Oncol Immunology*. 2017;6(11):e1353858. Doi: 10.1080/2162402X.2017.1353858
- Godder KT, Henslee-Downey PJ, Mehta J, Park BS, Chiang K-Y, Abhyankar S, et al. Long term disease-free survival in acute leukemia patients recovering with increased gammadelta T cells after partially mismatched related donor bone marrow transplantation. *Bone Marrow Transplant*. 2007;39(12):751–757. Doi: 10.1038/sj.bmt.1705650
- Ma Y, Aymeric L, Locher C, Mattarollo SR, Delahaye NF, Pereira P, et al. Contribution of IL-17-producing $\gamma\delta$ T cells to the efficacy of anticancer chemotherapy. *J Exp Med*. 2011;208(03):491–503. Doi: 10.1084/jem.20100269
- Lafont V, Sanchez F, Laprevotte E, Michaud H-A, Gros L, Eliaou J-F, et al. Plasticity of $\gamma\delta$ T cells: impact on the anti-tumor response. *Front Immunol*. 2014;5:622. Doi: 10.3389/fimmu.2014.00622
- Davey MS, Willcox CR, Hunter S, Kasatskaya SA, Remmerswaal EBM, Salim M, et al. The human V δ 2⁺ T-cell compartment comprises distinct innate-like V γ 9⁺ and adaptive V γ 9⁻ subsets. *Nat Commun*. 2018;9(01):1760. Doi: 10.1038/s41467-018-04076-0
- Girardi M, Glusac E, Filler RB, Roberts SJ, Propperova I, Lewis J, et al. The distinct contributions of murine T cell receptor (TCR) gammadelta+ and TCRalphabeta+ T cells to different stages of chemically induced skin cancer. *J Exp Med*. 2003;198(05):747–755. Doi: 10.1084/jem.20021282
- Gaafar A, Aljurf MD, Al-Sulaiman A, Iqniebi A, Manogaran PS, Mohamed GEH, et al. Defective gammadelta T-cell function and granzyme B gene polymorphism in a cohort of newly diagnosed breast cancer patients. *Exp Hematol*. 2009;37(07):838–848. Doi: 10.1016/j.exphem.2009.04.003
- Niu C, Jin H, Li M, Xu J, Xu D, Hu J, et al. In vitro analysis of the proliferative capacity and cytotoxic effects of ex vivo induced natural killer cells, cytokine-induced killer cells, and gamma-delta T cells. *BMC Immunol*. 2015;16:61. Doi: 10.1186/s12865-015-0124-x
- Chapman NM, Chi H. Hallmarks of T-cell exit from quiescence. *Cancer Immunol Res*. 2018;6(05):502–508. Doi: 10.1158/2326-6066.CIR-17-0605
- Ferrarini M, Ferrero E, Dagna L, Poggi A, Zocchi MR. Human gammadelta T cells: a nonredundant system in the immune-surveillance against cancer. *Trends Immunol*. 2002;23(01):14–18. Doi: 10.1016/s1471-4906(01)02110-x
- Street SEA, Hayakawa Y, Zhan Y, Lew AM, MacGregor D, Jamieson AM, et al. Innate immune surveillance of spontaneous B cell lymphomas by natural killer cells and gammadelta T cells. *J Exp Med*. 2004;199(06):879–884. Doi: 10.1084/jem.20031981
- Liu Z, Eltoum IEA, Guo B, Beck BH, Cloud GA, Lopez RD. Protective immunosurveillance and therapeutic antitumor activity of gammadelta T cells demonstrated in a mouse model of prostate cancer. *J Immunol*. 2008;180(09):6044–6053. Doi: 10.4049/jimmunol.180.9.6044
- Lança T, Costa MF, Gonçalves-Sousa N, Rei M, Grosso AR, Penido C, et al. Protective role of the inflammatory CCR2/CCL2 chemokine pathway through recruitment of type 1 cytotoxic $\gamma\delta$ T lymphocytes to tumor beds. *J Immunol*. 2013;190(12):6673–6680. Doi: 10.4049/jimmunol.1300434
- Born WK, Reardon CL, O'Brien RL. The function of gammadelta T cells in innate immunity. *Curr Opin Immunol*. 2006;18(01):31–38. Doi: 10.1016/j.coi.2005.11.007
- Yang Y, Xu C, Wu D, Wang Z, Wu P, Li L, et al. $\gamma\delta$ T cells: crosstalk between microbiota, chronic inflammation, and colorectal cancer. *Front Immunol*. 2018;9:1483. Doi: 10.3389/fimmu.2018.0148
- Zhao Y, Niu C, Cui J. Gamma-delta ($\gamma\delta$) T cells: friend or foe in cancer development? *J Transl Med*. 2018;16(01):3. Doi: 10.1186/s12967-017-1378-2
- Wu P, Wu D, Ni C, Ye J, Chen W, Hu G, et al. $\gamma\delta$ T17 cells promote the accumulation and expansion of myeloid-derived suppressor cells in human colorectal cancer. *Immunity*. 2014;40(05):785–800. Doi: 10.1016/j.immuni.2014.03.013
- Gentles AJ, Newman AM, Liu CL, Bratman SV, Feng WO, Kim D, et al. The prognostic landscape of genes and infiltrating immune cells across human cancers. *Nat Med*. 2015;21(08):938–945. Doi: 10.1038/nm.3909
- Gao Y, Yang W, Pan M, Scully E, Girardi M, Augenlicht LH, et al. $\gamma\delta$ T cells provide an early source of interferon γ in tumor immunity. *J Exp Med*. 2003;198(03):433–442. Doi: 10.1084/jem.20030584
- He W, Hao J, Dong S, Gao Y, Tao J, Chi H, et al. Naturally activated V γ 4 $\gamma\delta$ T cells play a protective role in tumor immunity through expression of eomesodermin. *J Immunol*. 2010;185(01):126–133. Doi: 10.4049/jimmunol.0903767
- Sebestyen Z, Prinz I, Déchanet-Merville J, Silva-Santos B, Kuball J. Translating gammadelta ($\gamma\delta$) T cells and their receptors into cancer cell therapies. *Nat Rev Drug Discov*. 2020;19(03):169–184. Doi: 10.1038/s41573-019-0038-z
- Dieli F, Vermijlen D, Fulfaro F, Caccamo N, Meraviglia S, Cicero G, et al. Targeting human $\gamma\delta$ T cells with zoledronate and interleukin-2 for immunotherapy of hormone-refractory prostate cancer. *Cancer Res*. 2007;67(15):7450–7457. Doi: 10.1158/0008-5472.CAN-07-0199
- Poccia F, Gioia C, Martini F, Sacchi A, Piacentini P, Tempestilli M, et al. Zoledronic acid and interleukin-2 treatment improves immunocompetence in HIV-infected persons by activating Vgamma9Vdelta2 T cells. *AIDS*. 2009;23(05):555–565. Doi: 10.1097/QAD.0b013e3283244619